Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
114.49
-3.83 (-3.24%)
At close: Jul 31, 2026, 4:00 PM EDT
116.76
+2.27 (1.98%)
After-hours: Jul 31, 2026, 7:54 PM EDT
Corcept Therapeutics Revenue
Corcept Therapeutics had revenue of $256.15M in the quarter ending June 30, 2026, with 31.74% growth. This brings the company's revenue in the last twelve months to $830.81M, up 16.02% year-over-year. In the year 2025, Corcept Therapeutics had annual revenue of $761.41M with 12.79% growth.
Revenue (ttm)
$830.81M
Revenue Growth
+16.02%
P/S Ratio
14.90
Revenue / Employee
$1,138,100
Employees
730
Market Cap
12.38B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 761.41M | 86.37M | 12.79% |
| Dec 31, 2024 | 675.04M | 192.67M | 39.94% |
| Dec 31, 2023 | 482.38M | 80.52M | 20.04% |
| Dec 31, 2022 | 401.86M | 35.88M | 9.80% |
| Dec 31, 2021 | 365.98M | 12.10M | 3.42% |
| Dec 31, 2020 | 353.87M | 47.39M | 15.46% |
| Dec 31, 2019 | 306.49M | 55.24M | 21.99% |
| Dec 31, 2018 | 251.25M | 92.05M | 57.82% |
| Dec 31, 2017 | 159.20M | 77.88M | 95.77% |
| Dec 31, 2016 | 81.32M | 31.04M | 61.72% |
| Dec 31, 2015 | 50.29M | 23.74M | 89.39% |
| Dec 31, 2014 | 26.55M | 16.19M | 156.36% |
| Dec 31, 2013 | 10.36M | 7.05M | 213.18% |
| Dec 31, 2012 | 3.31M | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | 29.00K | -180.00K | -86.12% |
| Dec 31, 2008 | 209.00K | -273.00K | -56.64% |
| Dec 31, 2007 | 482.00K | 188.00K | 63.95% |
| Dec 31, 2006 | 294.00K | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioMarin Pharmaceutical | 3.24B |
| Exelixis | 2.38B |
| Madrigal Pharmaceuticals | 1.28B |
| Bio-Techne | 1.21B |
| Axsome Therapeutics | 708.24M |
| Arrowhead Pharmaceuticals | 622.01M |
| Krystal Biotech | 417.30M |
| Cytokinetics | 105.82M |
CORT News
- 1 day ago - Corcept Therapeutics price target raised to $161 from $150 at Canaccord - TheFly
- 1 day ago - Corcept Therapeutics price target raised to $165 from $88 at Piper Sandler - TheFly
- 1 day ago - Corcept Therapeutics price target raised to $165 from $95 at H.C. Wainwright - TheFly
- 2 days ago - Corcept Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 2 days ago - Corcept Therapeutics Earnings release: Q2 2026 - Filings
- 2 days ago - Corcept Therapeutics Quarterly report: Q2 2026 - Filings
- 2 days ago - Corcept Therapeutics reports Q2 EPS 36c, consensus 5c - TheFly
- 2 days ago - Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update - Business Wire